Literature DB >> 23915592

Mechanical circulatory support and heart transplantation: donor and recipient factors influencing graft survival.

Simon Maltais1, Nikhil P Jaik2, Irene D Feurer3, Mark A Wigger4, Thomas G DiSalvo4, Kelly H Schlendorf4, Rashid M Ahmad2, Daniel J Lenihan4, John M Stulak5, Mary E Keebler4.   

Abstract

BACKGROUND: Mechanical circulatory support is an accepted strategy to bridge patients to heart transplantation (HTx). Among mechanical circulatory support patients who go on to HTx, factors associated with improved graft survival have not been fully elucidated.
METHODS: Using the Scientific Registry for Transplant Recipients, we identified adults who were treated with a left ventricular assist device (LVAD) or total artificial heart (TAH) before HTx. Kaplan-Meier and multivariate Cox regression models were used to identify patient, donor, and device characteristics associated with graft survival.
RESULTS: Between January 1997 and February 2012, 2,785 adults underwent HTx. Before HTx, 2,674 patients were treated with a LVAD (HeartMate XVE, 724; HeartMate II, 1,882; HeartWare, 68), and 111 were treated with a TAH. Follow-up averaged 25 ± 24 months. Gender mismatch occurred in 23%. Graft survival did not differ between LVAD groups (all p > 0.168), but TAH was associated with reduced graft survival compared with LVADs (p < 0.001). After controlling for device type (LVAD vs TAH), lower recipient pulmonary vascular resistance, shorter ischemic time, younger donor age, donor-to-recipient gender match, and higher donor-to-recipient body mass index ratio were independent predictors of longer graft survival (all p < 0.05).
CONCLUSIONS: TAH was associated with reduced graft survival after transplant, and survival did not differ between the LVAD device groups. Additional variables that were independently associated with graft survival were donor age, recipient peripheral vascular resistance, ischemic time, gender match, and donor-to-recipient body mass index ratio. Recognition of these factors may inform decisions regarding device support and donor suitability.
Copyright © 2013 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  27

Mesh:

Year:  2013        PMID: 23915592     DOI: 10.1016/j.athoracsur.2013.05.043

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  Mortality, rehospitalization, and post-transplant complications in gender-mismatched heart transplant recipients.

Authors:  Anne Jalowiec; Kathleen L Grady; Connie White-Williams
Journal:  Heart Lung       Date:  2017-05-10       Impact factor: 2.210

2.  How to cope with a temporarily aborted transplant program: solutions for a prolonged waiting period.

Authors:  Frédéric Vanden Eynden; Martine Antoine; Bachar El Oumeiri; Marie-Luce Chirade; Jean-Luc Vachiéry; Guido J Van Nooten
Journal:  Ann Transl Med       Date:  2015-11

Review 3.  Donor selection in heart transplantation.

Authors:  Ahmet Kilic; Sitaramesh Emani; Chittoor B Sai-Sudhakar; Robert S D Higgins; Bryan A Whitson
Journal:  J Thorac Dis       Date:  2014-08       Impact factor: 2.895

4.  Increasing heart transplant donor pool by liberalization of size matching.

Authors:  Luise Holzhauser; Teruhiko Imamura; Nikhil Bassi; Takeo Fujino; Daisuke Nitta; Anthony J Kanelidis; Nikhil Narang; Gene Kim; Jayant Raikhelkar; Catherine Murks; David Onsager; Tae Song; Takeyoshi Ota; Valluvan Jeevanandam; Gabriel Sayer; Nir Uriel
Journal:  J Heart Lung Transplant       Date:  2019-08-24       Impact factor: 10.247

5.  Pulmonary function assessment post-left ventricular assist device implantation.

Authors:  Pavol Sajgalik; Chul-Ho Kim; John M Stulak; Sudhir S Kushwaha; Simon Maltais; David L Joyce; Lyle D Joyce; Bruce D Johnson; John A Schirger
Journal:  ESC Heart Fail       Date:  2018-10-12

Review 6.  Influence of Sex-Mismatch on Prognosis After Heart Transplantation.

Authors:  Ana Ayesta
Journal:  Front Cardiovasc Med       Date:  2021-03-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.